UBS: Lower NAGACORP (03918) target price to 6.4 Hong Kong dollars, signs of recovery in VIP business demand.
Foreign direct investment (FDI) continues to flow into Cambodia, coupled with the upcoming visa exemption between China and Cambodia, which will help drive demand for Chinese tourists.
UBS released a research report stating that NAGACORP (03918) performed as expected in the second half of last year, but faced pressure on VIP business demand due to the impact of the crackdown on fraud centers and the tense situation at the Thailand-Cambodia border. Management indicated that VIP business demand has started to recover after the ceasefire agreement in December, and they plan to continue expanding their marketing team to attract international customers this year. In addition, foreign direct investment (FDI) continues to flow into Cambodia, and the upcoming visa-free policy between China and Cambodia is expected to drive demand from Chinese tourists. The bank maintained a "buy" rating with a target price lowered from 6.8 Hong Kong dollars to 6.4 Hong Kong dollars.
The company expects capital expenditure of around $170 million by 2026, mainly for renovating Naga 1 and Naga 2, as well as introducing smart gaming table technology. Operating expenses are expected to increase in the low to mid-single digits, but management has not provided an updated development timeline or scale for Naga 3. Despite geopolitical turmoil, management expects limited impact on operations. The group will continue to adopt a cautious dividend policy to maintain financial flexibility to address risks and the final plan for Naga 3 and capital expenditure.
Related Articles

UNITED LAB(03933): Phase II clinical study of class 1 innovative drug UBT251 injection has been completed in Chinese type 2 diabetes patients.

COSCO SHIP INTL(00517) will distribute a final dividend of HK$0.19 per share on July 15th.

POP MART (09992) will distribute a final dividend of HKD 2.3817 per share on May 28th.
UNITED LAB(03933): Phase II clinical study of class 1 innovative drug UBT251 injection has been completed in Chinese type 2 diabetes patients.

COSCO SHIP INTL(00517) will distribute a final dividend of HK$0.19 per share on July 15th.

POP MART (09992) will distribute a final dividend of HKD 2.3817 per share on May 28th.

RECOMMEND

Pace Of Public Fund Issuance Slows, Hong Kong Stocks Become A Primary Focus
24/03/2026

Jensen Huang In‑Depth Interview: Token Economy Surge, AI Computing’s Share Of GDP To Multiply One Hundredfold, NVIDIA’s $10 Trillion Valuation Inevitable
24/03/2026

Are U.S.‑Iran Talks Genuine? At Minimum, Wall Street Read A Clear Signal From Trump’s Five‑Minute Rally
24/03/2026


